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Abstract
We investigated the effects of low ouabain concentrations on systolic (SAP) and diastolic (DAP) arterial pressures and on pres-
sor reactivity in 3-month-old male spontaneously hypertensive rats (SHR). Arterial blood pressure (BP) and pressor reactivity to 
phenylephrine (PHE) were investigated before and after 0.18 μg/kg ouabain administration (N = 6). The influence of hexametho-
nium (N = 6), canrenone (N = 6), enalapril (N = 6), and losartan (N = 6) on ouabain actions was evaluated. Ouabain increased 
BP (SAP: 137 ± 5.1 to 150 ± 4.7; DAP: 93.7 ± 7.7 to 116 ± 3.5 mmHg; P < 0.05) but did not change PHE pressor reactivity. 
Hexamethonium reduced basal BP in control but not in ouabain-treated rats. However, hexamethonium + ouabain increased 
DAP sensitivity to PHE. Canrenone did not affect basal BP but blocked ouabain effects on SAP. However, after canrenone + 
ouabain administration, DAP pressor reactivity to PHE still increased. Enalapril and losartan reduced BP and abolished SAP 
and DAP responses to ouabain. Enalapril + ouabain reduced DAP reactivity to PHE, while losartan + ouabain reduced SAP 
and DAP reactivity to PHE. In conclusion, a small dose of ouabain administered to SHR increased BP without altering PHE 
pressor reactivity. Although the renin-angiotensin system (RAS), Na+ pump and autonomic reflexes are involved in the effects 
of ouabain on PHE reactivity, central mechanisms might blunt the actions of ouabain on PHE pressor reactivity. The effect of 
ouabain on SAP seems to depend on the inhibition of both Na+ pump and RAS, whereas the effect on DAP seems to depend 
only on RAS. 
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Introduction
The existence of an endogenous steroidal ligand that 
inhibits Na+ pump activity in humans and other mammals 
has been well established (1). This inhibitor was charac-
terized as ouabain or a stereoisomer of ouabain (2,3). 
Endogenous ouabain increases in patients with essential 
hypertension and correlates with blood pressure (4,5). In 
addition, plasma ouabain levels increase in several hy-
pertension models (6,7) and several studies have shown 
that acute or chronic administration of ouabain increases 
blood pressure in rodents (8-10). These results suggest a 
possible association between ouabain and the genesis or 
development and maintenance of arterial hypertension. 
 An explanation for this association is that ouabain binds 
to the α-subunit of the Na+ pump, inhibiting its activity. 
Inhibition of this pump increases intracellular Na+, which 
reduces the activity of the sarcolemmal Na+/Ca2+ exchanger 
and thereby reduces Ca2+ extrusion. Consequently, the 
intracellular Ca2+ concentration increases and is taken 
up by the sarcoplasmic reticulum, which, upon activation, 
releases more calcium and increases the vascular smooth 
muscle tone (11). According to Vassallo et al. (12) and 
Rossoni et al. (9), acute treatment with ouabain enhances 
the vascular reactivity to vasopressor agents, and Barker 
et al. (13) reported that it also enhances the release of 
norepinephrine from the perivascular adrenergic nerve 
endings. Additionally, the hypertension induced by oua-
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bain has been associated with central mechanisms that 
increase sympathetic tone, subsequent to the activation 
of the cerebral renin-angiotensin (14,15) and endothelin 
systems (16). Thus, in addition to peripheral mechanisms, 
central mechanisms may contribute to the ouabain-induced 
elevation of arterial blood pressure. 
Previous reports have shown that acute administration 
of very low doses of ouabain increases the blood pressure 
of spontaneously hypertensive rats (SHR) but not of normo-
tensive rats (9,12). In the perfused tail vascular bed, 1 nM 
ouabain increases the pressor response to phenylephrine 
only in hypertensive rats by a mechanism involving an in-
crease in the activity of endothelial angiotensin-converting 
enzyme (ACE) and the local synthesis of angiotensin II 
(17). However, the mechanism(s) by which acute admin-
istration of nanomolar concentrations of ouabain, similar 
to the normal plasma concentrations (2), exerts its effects 
in vivo on blood pressure and on pressor responses to 
vasoconstrictor agents is still under debate. It is not clear 
yet which is the contribution of central (15,16) or peripheral 
mechanisms (9,12,17), or of both simultaneously to this 
increased pressor response.
Since SHR have higher sensitivity to ouabain at nano-
molar concentration (12), our aim was to investigate the 
effects of ouabain in vivo on arterial pressure and pressor 
reactivity to phenylephrine and to evaluate the role of au-
tonomic reflexes, the renin-angiotensin system and Na+ 
pump activity. 
Material and Methods
Studies were performed in 3-month-old male SHR (N = 
57). All experiments were conducted in compliance with the 
guidelines for biomedical research as stated by the Brazilian 
Societies of Experimental Biology. The experimental proto-
col was approved by the Ethics Committee of the Institute 
of Biomedical Sciences, EMESCAM (Protocol #003/2007). 
All rats had free access to water and rat chow. 
Rats were anesthetized with urethane (1.2 g/kg, ip), 
and, after loss of the righting reflex, the carotid artery and 
jugular vein were dissected and cannulated with a polyeth-
ylene catheter (PE-50) and filled with heparinized saline 
(50 U/mL) for arterial blood pressure measurements and 
drug infusions, respectively. Arterial blood pressure was 
measured using a pressure transducer (Statham P23 AA, 
USA) connected to a preamplifier and to an acquisition 
system (model MP100A, BIOPAC System, Inc., USA). The 
protocols were performed with anesthetized rats due to 
the duration of the experiment and the necessity of stable 
arterial pressure maintenance. 
Hemodynamic effects of ouabain 
To determine whether nanomolar amounts of ouabain af-
fected the arterial blood pressure and the pressor response 
to phenylephrine, ouabain (0.18 μg/kg, iv; in a volume of 17 
μL/100 g rat weight) was administered. This dose of ouabain 
was expected to produce nanomolar levels of circulating 
ouabain (approximately 1.5 nM) similar to that found in the 
plasma of normotensive subjects (2), considering that the 
amount injected would be diluted in 20 mL of extracellular 
fluid per 100 g body weight. This dose produced an increase 
in blood pressure in hypertensive but not in normotensive 
animals, showing that hypertensive animals are more 
sensitive to ouabain (12).
Systolic (SAP) and diastolic (DAP) arterial pressures 
were monitored continuously. SAP was taken as an index 
of left ventricular function while DAP was taken as an index 
of peripheral resistance. After a 30-min stabilization period, 
the pressor reactivity protocol was performed by injecting 
increasing concentrations of phenylephrine in bolus (0.03 
to 100 μg/kg) administered in small volumes (5 μL/100 g 
rat weight). After ouabain administration, all animals (N = 6) 
were followed for 1 h. SAP, DAP and heart rate (HR) were 
then measured again, and another dose-response curve 
to phenylephrine was constructed. 
To ensure that the effects were not dependent on time, 
a time control experiment was performed. Saline (0.9%, iv) 
was administered to another group of rats under the same 
conditions. The stability of the protocol was confirmed by 
the maintenance of SAP and DAP (data not shown).
Ganglionic blockade
The ganglionic blocker hexamethonium (5 mg/kg) was 
used to investigate the modulation of the effects of oua-
bain by autonomic reflex control. To avoid a large drop of 
arterial pressure, only a partial ganglionic blockade was 
obtained with this concentration of hexamethonium. Due 
to the duration of the experiment two groups were used: 
one treated with hexamethonium and the other treated 
with hexamethonium plus ouabain. In the control group, 
after arterial pressure stabilization, a phenylephrine dose-
response curve was constructed, and SAP, DAP and HR 
were measured. Next, hexamethonium was administered 
and after 30 min another concentration-response curve to 
phenylephrine was constructed. In the hexamethonium plus 
ouabain group, SAP, DAP and HR were measured after 
arterial pressure stabilization. Hexamethonium plus ouabain 
was then administered. After 60 min another phenylephrine 




To determine whether the effects of ouabain were caused 
by inhibition of the Na+ pump activity, canrenone (1 mg/
kg) a blocker of ouabain effects, was used because of its 
antagonistic properties at the digitalis receptor site (18,19). 
This small concentration of canrenone was used to avoid 
the changes induced by larger concentrations in myocardial 
contractility, vascular tone or arterial blood pressure, as 
previously reported (18). 
Ouabain enhances hypertension in SHR 769
www.bjournal.com.br Braz J Med Biol Res 43(8) 2010
Also, two groups were used, one treated with canrenone 
and the other treated with canrenone plus ouabain. The 
same protocol as described above for hexamethonium was 
performed using canrenone.
 
ACE and AT1 blockade
In the last two protocols, the participation of the renin-
angiotensin system was investigated by using the ACE in-
hibitor enalapril maleate (5 mg/kg), and losartan (10 mg/kg), 
which is an angiotensin type 1 (AT1) receptor antagonist. 
Due to the duration of the experiment, these proto-
cols were performed with different groups of rats, one for 
losartan or enalapril maleate and the other for losartan or 
enalapril maleate plus ouabain. The same protocol as used 
for carenone was then performed using enalapril maleate 
or losartan.
Drugs used 
Ouabain octahydrate, l-phenylephrine hydrochloride, 
hexamethonium hydrochloride, canrenone, losartan, enal-
april maleate, and urethane were purchased from Sigma 
(USA), and heparin was purchased from Roche Pharma-
ceuticals (Brazil). 
Statistical analysis 
Data are reported as means ± SEM. Non-linear regres-
sion analysis for the determination of the maximum change 
in pressure (Emax) and the logarithm of the dose producing 
one-half of Emax (-log EC50 or pD2) were employed to 
obtain fitting curves using the GraphPad Prism Software 
(USA). To compare the effect of different drugs on the 
response to phenylephrine, some results are reported as 
“differences of areas under the concentration-response 
curves” (dAUC) for control and experimental situations. 
The AUC was calculated from each concentration-response 
curve, and the differences are reported as a percentage 
of AUC for the corresponding control situation. Data were 
analyzed statistically by the Student t-test and ANOVA. 
When ANOVA showed a significant effect of treatment, the 
Tukey post hoc test was used to compare means. P < 0.05 
was considered to be significant. 
Results
Table 1 shows that 1 h after the administration of ouabain 
(iv), baseline SAP and DAP significantly increased. How-
ever, ouabain did not change HR. The systolic and diastolic 
pressure reactivity to phenylephrine did not change after 
ouabain administration, as shown in Figure 1. Tables 2 and 
3 also show that Emax and pD2 did not change. 
To investigate whether the reflex activity involving 
the autonomic nervous system could mask the effects of 
ouabain, a ganglionic blocker was used. As expected, the 
administration of hexamethonium reduced baseline SAP 
and DAP, but these parameters increased after ouabain 
treatment (Table 1).
The effects on pressor reactivity were investigated using 
phenylephrine, a vascular smooth muscle α1-adrenoceptor 
agonist. Under control conditions, the concentration-
response curves to phenylephrine after hexamethonium 
showed similar values of pD2 and Emax for both SAP and 
DAP. After ouabain administration, the systolic pressure 
reactivity to phenylephrine did not change, but the diastolic 
sensitivity to phenylephrine increased (Figure 2, Tables 
2 and 3). We observed an upward displacement of the 
concentration-response curve of DAP to phenylephrine 
after ouabain administration. Two-way randomized ANOVA, 
performed in order to evaluate the behavior of the concen-
tration-response DAP curves, significance was found. Then, 
to better understand this effect, we generated dAUCs and 
observed a large increase in diastolic pressure reactivity 
to phenylephrine after treatment with hexamethonium plus 
ouabain (Figure 2C). 
Canrenone, an Na+ pump blocker, was used to evaluate 
the influence of the Na+ pump on the actions of ouabain. 
Canrenone administration did not alter baseline SAP or 
DAP. One hour after ouabain administration, the SAP of 
rats previously treated with canrenone did not change, 
Table 1. Baseline systolic and diastolic arterial pressure (SAP 
and DAP) and heart rate (HR) of all groups.
Groups SAP (mmHg) DAP (mmHg) HR (bpm)
Ct (N = 6) 137 ± 5.1 93.7 ± 7.7 394 ± 10
Oua (N = 6) 150 ± 4.7* 116.0 ± 3.5* 381 ± 17
Ct (N = 6) 149 ± 5.2 103 ± 5.9 359 ± 11
Hexa (N = 6) 118 ± 4.9* 79 ± 7.4* 336 ± 12
Hexa + Oua (N = 6) 145 ± 4.4+ 103 ± 7.8+ 348 ± 10
Ct (N = 6) 140 ± 4.2 94.8 ± 4.4 341 ± 14
Can (N = 6) 146 ± 9.8 96.8 ± 7.3 362 ± 6
Can + Oua (N = 6) 155 ± 2.7 114.0 ± 4.2*+ 362 ± 8
Ct (N = 6) 137 ± 3.9 77.0 ± 5.0 330 ± 9
Ena (N = 6) 115 ± 5.3* 50.0 ± 1.9* 326 ± 10
Ena + Oua (N = 6) 122 ± 6.4 49.5 ± 3.4* 330 ± 13
Ct (N = 6) 128 ± 4.2 72.5 ± 4 332 ± 13
Los (N = 6) 113 ± 2.9* 57.1 ± 5* 337 ± 18
Los + Oua (N = 6) 110 ± 3.7* 53.6 ± 4.9* 334 ± 13
Ct = measurements made under control conditions; Oua = 
measurements made 1 h after ouabain administration; Hexa = 
hexamethonium; Can = canrenone; Ena = enalapril maleate; Los 
= losartan. Data are reported as means ± SEM. *P < 0.05 vs its 
control value. +P < 0.05 Hexa + Oua vs Hexa; Can + Oua vs Can 
(one-way randomized ANOVA). 
770 F.D.M. Siman et al.
www.bjournal.com.brBraz J Med Biol Res 43(8) 2010
but the DAP increased (Table 1). In ouabain-untreated 
rats, canrenone did not alter the pD2 and Emax of the SAP 
and DAP concentration-response curves to phenyleph-
rine. Ouabain administration also did not change the pD2 
and Emax of the SAP concentration-response curves to 
phenylephrine (Tables 2 and 3). However, we observed 
Figure 1. Changes in systolic (A) and diastolic (B) arterial pressure (SAP and DAP), and basal pressure in the dose-response curve 
for phenylephrine before (Ct; N = 6) and 1 h after ouabain (Oua; N = 6) administration. Data are reported as means ± SEM (Student 
t-test).
Table 2. Maximal response (Emax) and sensitivity (pD2) of sys-
tolic arterial pressure concentration-response curves to phe-
nylephrine of all groups.
Groups Emax (mmHg) pD2
Ct (N = 6) 278 ± 17.3 2.20 ± 0.7
Oua (N = 6) 273 ± 18.9 2.95 ± 0.05
Ct (N = 6) 276 ± 18.0 2.80 ± 0.09
Hexa (N = 6) 285 ± 12.7 2.89 ± 0.07
Hexa + Oua (N = 6) 294 ± 10.8 2.97 ± 0.14
Ct (N = 6) 305 ± 7 2.7 ± 0.06
Can (N = 6) 301 ± 8.2 2.9 ± 0.05
Can + Oua (N = 6) 269 ± 19 2.8 ± 0.04
Ct (N = 6) 285 ± 2.3 2.78 ± 0.08
Ena (N = 6) 269 ± 5.4* 2.86 ± 0.2 
Ena + Oua (N = 6) 269 ± 3.8* 2.19 ± 0.21+
Ct (N = 6) 281 ± 8.1 2.7 ± 0.15
Los (N = 6) 275 ± 7.7 2.5 ± 0.10
Los + Oua (N = 6) 246 ± 6.9*+ 2.7 ± 0.06
Ct = measurements made under control conditions; Oua = 
measurements made 1 h after ouabain administration; Hexa = 
hexamethonium; Can = canrenone; Ena = enalapril maleate; Los 
= losartan. Data are reported as means ± SEM. *P < 0.05 vs its 
control value. +P < 0.05 Los + Oua vs Los; Ena + Oua vs Ena 
(one-way randomized ANOVA). 
Table 3. Maximal response (Emax) and sensitivity (pD2) of dia-
stolic arterial pressure concentration-response curves to phe-
nylephrine in all groups.
Groups Emax (mmHg) pD2
Ct (N = 6) 185 ± 4.4 2.78 ± 0.42
Oua (N = 6) 179 ± 5.8 3.09 ± 0.13
Ct (N = 6) 179 ± 12.8 2.95 ± 0.11
Hexa (N = 6) 185 ± 8.7 3.06 ± 0.13
Hexa + Oua (N = 6) 192 ± 6.0  3.34 ± 0.12*
Ct (N = 6) 184 ± 7.3  3.0 ± 0.28
Can (N = 6) 197 ± 4.8  3.1 ± 0.06
Can + Oua (N = 6) 186 ± 6  3.0 ± 0.07
Ct (N = 6) 176 ± 5.5  2.20 ± 0.70
Ena (N = 6) 155 ± 9.4  2.45 ± 0.57
Ena + Oua (N = 6) 157 ± 7.1  2.51 ± 0.15
Ct (N = 6) 173 ± 7.5 2.6 ± 0.52
Los (N = 6) 162 ± 5.7 2.9 ± 0.09
Los + Oua (N = 6) 159 ± 9.9 2.8 ± 0.11
Ct = measurements made under control conditions; Oua = 
measurements made 1 h after ouabain administration; Hexa = 
hexamethonium; Can = canrenone; Ena = enalapril maleate; Los 
= losartan. Data are reported as means ± SEM. *P < 0.05 vs its 
control value (one-way randomized ANOVA).
Ouabain enhances hypertension in SHR 771
www.bjournal.com.br Braz J Med Biol Res 43(8) 2010
a marked difference in the DAP concentration-response 
curves between groups when the first six phenylephrine 
concentrations were used (Figure 3B). We then performed 
a two-way randomized ANOVA to evaluate the behavior 
of the whole concentration-response DAP curves, which 
revealed significance. The effects of the first six phenyleph-
rine concentrations were then appreciated by comparing 
the three groups (control, canrenone and canrenone plus 
ouabain) using dAUC. It was observed that stimulation with 
low concentrations of phenylephrine induced increased 
diastolic pressure reactivity after treatment with canrenone 
plus ouabain (Figure 3C). 
Enalapril and losartan were used to investigate the effect 
of the renin-angiotensin system on the actions of ouabain 
on blood pressure and pressure reactivity to phenylephrine. 
Administration of both drugs reduced the baseline SAP and 
DAP. Ouabain administration to rats previously treated with 
enalapril or losartan did not change the baseline SAP and 
DAP, suggesting that AT1 blockade or ACE inhibition abol-
ished the increase in SAP and DAP produced by ouabain 
(Table 1). Losartan administration did not change pressure 
reactivity to phenylephrine for SAP and DAP. However, af-
ter ouabain administration, losartan produced a downward 
displacement of the whole concentration-response curve of 
SAP and DAP to phenylephrine. For SAP, Emax was reduced 
without changing pD2 (Figure 4A, Table 2) and for DAP, these 
parameters did not change (Figure 4B, Table 3). dAUCs were 
used to analyze the whole effects of losartan and losartan plus 
ouabain, suggesting a reduction of the systolic and diastolic 
pressure reactivity to phenylephrine after treatment with the 
combination of the two drugs (Figure 4C,D). 
When evaluating SAP, we observed that enalapril 
reduced Emax under non-treated conditions but did not 
change the pD2 to phenylephrine. Following ouabain 
administration, pD2 was also reduced when compared to 
the non-treated condition while Emax was more reduced 
(Figure 5A, Table 2). For DAP, these parameters, Emax and 
pD2, did not show significant changes (Figure 5B, Table 3). 
However, when observing the behavior of the curves, we 
noticed a downward displacement in the concentration-
response curve for DAP to phenylephrine after ouabain 
administration. With dAUC generation, we could observe 
a reduction of DAP reactivity to phenylephrine after treat-
ment with enalapril plus ouabain, which was similar to the 
behavior of the losartan plus ouabain group (Figure 5C,D), 
but not for SAP. 
Figure 2. Dose-response curve of systolic (A) and diastolic (B) arterial pressure (SAP and DAP) and basal pressure to phenylephrine 
before (Ct; N = 6) and after hexamethonium (Hexa; N = 6) and after hexamethonium plus ouabain (Hexa + Oua; N = 6) administration. 
*P < 0.05 for Hexa + Oua vs Ct (one-way randomized ANOVA). Panel C shows differences in area under the concentration-response 
curve (dAUC) of DAP to phenylephrine before and after hexamethonium in control and ouabain-treated rats. Data are reported as 
means ± SEM. *P < 0.05 vs Control (Student t-test). 
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Figure 3. Dose-response curve of systolic (A) and diastolic (B) arte-
rial pressure (SAP and DAP) and basal pressure to phenylephrine 
before (Ct; N = 6) and after canrenone (Can; N = 6) and after can-
renone plus ouabain (Can + Oua; N = 6) administration. Panel C 
shows differences in area under the concentration-response curve 
(dAUC) of DAP to phenylephrine before and after canrenone in con-
trol and ouabain-treated rats. Data are reported as means ± SEM. *P 
< 0.05 vs Control (Student t-test). 
Figure 4. Dose-response curve of systolic (A) and diastolic (B) arterial pressure (SAP and DAP) and basal pressure to phenylephrine 
before (Ct; N = 6) and after losartan (Los; N = 6) and after losartan plus ouabain (Los + Oua; N = 6) administration. *P < 0.05 Los + Oua 
vs Ct and vs Los (one-way randomized ANOVA). Panels C and D show differences in area under the concentration-response curve 
(dAUC) of SAP (C) and DAP (D) to phenylephrine before and after losartan in control and ouabain-treated rats. Data are reported as 
means ± SEM. *P < 0.05 vs Control (Student t-test). 
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Discussion 
The results presented here suggest that the acute ad-
ministration of a small concentration of ouabain enhances 
hypertension in SHR, increasing systolic and diastolic 
arterial pressure without altering the pressor reactivity to 
phenylephrine. This increase in blood pressure seems to 
depend on ouabain inhibiting the Na+ pump, which increases 
systolic pressure, and activating the local renin-angiotensin 
system, which increases diastolic pressure. The lack of 
the effect of ouabain on phenylephrine pressor reactivity 
seems to depend on central mechanisms that might blunt 
these changes in pressor reactivity. It is important to em-
phasize that anesthesia with urethane reduces systolic and 
diastolic blood pressure in SHR, but when compared with 
normotensive animals, the blood pressure levels of these 
animals were still elevated, as previously reported by our 
group (9,12,17).
Previous reports have shown that nanomolar concentra-
tions resulting from acute ouabain administration increased 
the blood pressure of SHR, of rats with renovascular hy-
pertension and rats with L-NAME-induced hypertension, 
whereas no change in blood pressure was observed in 
normotensive rats (9,12). This occurs also with chronic 
ouabain treatment, as observed by Xavier et al. (20). The 
cited study demonstrated that ouabain treatment for 5 
weeks increased the blood pressure of SHR but not of 
normotensive rats (20). Our results show that acute admin-
istration of a small concentration of ouabain enhances SHR 
hypertension. The increase in baseline systolic pressure 
might result from the classic effect of ouabain promoting a 
positive inotropic effect by inhibiting the Na+ pump (11,21) 
and/or increasing the sympathetic tone (14). The increase in 
baseline diastolic pressure suggests that ouabain increases 
pressor reactivity to vasoconstrictor agents and, conse-
quently, the peripheral vascular resistance, as previously 
demonstrated (12,17,22). 
Since normal plasma concentrations of ouabain are in 
the nanomolar range (2,23), the purpose of the present study 
was to investigate the mechanism(s) of ouabain action on 
arterial pressure using a dose that might generate a blood 
concentration near the physiological range by dilution in 20 
mL of extracellular fluid per 100 g body weight. 
In the present study, ouabain increased the systolic and 
diastolic arterial pressures. Therefore, we investigated some 
possibilities to explain these effects. Given that ouabain 
might induce hypertension by central mechanisms, we 
first investigated the possible influence of autonomic reflex 
Figure 5. Dose-response curve of systolic (A) and diastolic (B) arterial pressure (SAP and DAP) and basal pressure to phenylephrine 
before (Ct; N = 6) and after enalapril maleate (Ena; N = 6) and after enalapril maleate plus ouabain (Ena + Oua; N = 6) administration. 
*P < 0.05 Ct vs Ena and vs Ena + Oua, +P < 0.05 Ena + Oua vs Ena (one-way randomized ANOVA). Panels C and D show differences 
in area under the concentration-response curve (dAUC) of SAP (C) and DAP (D) to phenylephrine before and after enalapril maleate 
in control and ouabain-treated rats. Data are reported as means ± SEM. *P < 0.05 vs Control (Student t-test).
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modulation via ganglionic blockade with hexamethonium. 
The central mechanism is associated with an increased 
sympathetic tone and resetting of the baroreceptor reflex 
(14). Considering that sympathetic hyperactivity and hy-
pertension induced by ouabain are prevented by AT1 and 
endothelin-1 (ET1) receptor blockade (16,24), the central 
renin-angiotensin and endothelin systems are suggested 
to be the sympathoexcitatory components involved in the 
hypertensinogenic effect of ouabain. At the same time, 
previous reports have shown that in reflex-blocked rats 
hexamethonium prevents the hypertension induced by 
chronic ouabain treatment (25). However, our findings 
showed that the ouabain effect of increasing the baseline 
arterial pressure was not altered after ganglionic blockade 
with hexamethonium, suggesting a peripheral effect. The 
present findings agree with results reported by Barker et al. 
(13) who demonstrated that acute administration of small 
concentrations of ouabain increases the blood pressure 
of normotensive rats, and this effect is not modulated by 
autonomic reflexes but rather depends on ouabain actions 
on sympathetic nerve endings and on vascular smooth 
muscle. These observations suggest that under ganglionic 
blockade the increase of baseline systolic and diastolic 
arterial pressures evoked by ouabain is not mediated by 
central nervous system mechanisms. 
However, when we tested the pressor reactivity to 
phenylephrine, we observed that co-treatment with hex-
amethonium plus ouabain increased the diastolic pres-
sure sensitivity but not the systolic pressure reactivity to 
phenylephrine. These findings suggest that in conditions 
in which the autonomic reflexes are functional, central 
mechanisms might modulate ouabain actions during phe-
nylephrine administration. 
Previous reports have shown a putative association 
between ouabain and the genesis or development and 
maintenance of arterial hypertension (8-10). The possible 
explanation for this association is that ouabain binds to 
the α-subunit of the Na+ pump, inhibiting its activity (11). 
However, the underlying mechanisms by which ouabain el-
evates blood pressure have not been completely described. 
A recent study showed that chronic ouabain administration 
induces up-regulation of the α2 Na+ pump and Na+/Ca2+ 
exchanger type 1 expression in arterial smooth muscle, 
probably trying to compensate for the ouabain-induced 
reduction in sodium pump activity (26). This increased Ca2+ 
signaling may explain the augmented myogenic responses 
and enhanced phenylephrine-induced vasoconstriction in 
arteries from ouabain-induced hypertensive rats, as well 
as the high blood pressure (26). 
Thus, given that ouabain has the ability to inhibit the Na+ 
pump in several tissues, including vascular smooth muscle 
(22), this could explain its pressor effects on baseline dia-
stolic pressure. We then investigated whether the ouabain 
pressor effects are related to the inhibitory actions on the 
Na+ pump. Previous reports have suggested that canrenone 
interacts with the digitalis receptor site of the Na+ pump 
and antagonizes the binding of ouabain (19,27). Indeed, 
acute administration of canrenone blocks the positive ino-
tropic effect of ouabain in isolated perfused hearts (18). To 
clarify this issue, we first tested the effects of canrenone or 
canrenone plus ouabain on arterial pressure. The present 
findings show that canrenone abolished the pressor effect 
of ouabain on the systolic pressure, suggesting that this 
effect is associated with inhibition of the Na+ pump. 
In contrast, canrenone did not abolish the pressor effect 
of ouabain on diastolic pressure. This is the first suggestion 
that ouabain may have a mechanism of action on diastolic 
pressure that is not dependent on the Na+ pump. Previous 
reports have demonstrated that ouabain and a series of 
structurally related analogs have hypertensinogenic activity, 
regardless of their potency as Na+ pump inhibitors (28). An 
additional explanation by Ward et al. (29) suggested that 
adrenocortical cells express ouabain receptors that are dis-
tinct from the Na+ pumps. These findings could explain why 
the pressor effect of ouabain on the baseline DAP seems 
not to be dependent on its action on the Na+ pump.
We also tested the effects of canrenone on the pressor 
reactivity to phenylephrine of diastolic and systolic pressure. 
When analyzing dAUCs for diastolic pressure, we observed 
that, after the administration of canrenone plus ouabain, the 
effects on diastolic pressure were enhanced. This finding 
suggests that the actions of ouabain on diastolic pressure 
are not dependent on binding to the Na+ pump. This find-
ing also reinforces our results regarding the increase in 
baseline diastolic pressure, since, in spite of the blockade 
of the Na+ pump by canrenone, ouabain continued to exert 
its pressor effect. 
In addition, studies from our laboratory have dem-
onstrated that acute administration of low ouabain con-
centrations stimulates local ACE activity and increases 
angiotensin II release in the tail vascular bed of SHR 
(17). On the other hand, the central mechanism already 
described suggests that ouabain stimulates the brain 
renin-angiotensin system, leading to the production of 
angiotensin II that further increases sympathetic tone and 
ultimately increases arterial blood pressure (14). Indeed, 
it has been reported that acute central administration of 
ouabain causes sympathoexcitatory and pressor effects in 
rats (30). In addition, the acute hypertensinogenic effect of 
ouabain is attenuated in transgenic rats that are deficient 
in brain angiotensinogen (31).
The participation of the renin-angiotensin system was 
then investigated, and the administration of enalapril and 
losartan abolished the effect of ouabain on baseline arterial 
pressure. Therefore, our results suggest that to increase 
baseline systolic pressure ouabain also stimulates the renin-
angiotensin system. Thus, an operational renin-angiotensin 
system is necessary for the effect of ouabain. Both findings, 
which involved the Na+ pump and renin-angiotensin system, 
might explain the increase in baseline systolic pressure 
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Regarding the baseline diastolic pressure, the action of 
ouabain could be mediated only by the stimulation of the 
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tensin II may act on vascular smooth muscle, promoting 
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consequently, the diastolic pressure (32). Considering 
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increases sympathoexcitatory activity (14), the sharp reduc-
tion of the pressor reactivity to phenylephrine after blockade 
of the renin-angiotensin system could be explained by a 
reduced stimulation of the sympathetic nervous system. 
Although no changes in phenylephrine reactivity were 
observed, after pharmacological interventions, it was pos-
sible to show the participation of the renin-angiotensin sys-
tem, the Na+ pump and the autonomic reflexes in the effects 
of ouabain. In addition, other mechanisms, possibly central 
ones, might blunt ouabain actions when phenylephrine 
concentration-response curves are constructed. Regard-
ing the changes in baseline blood pressure, the effect of 
ouabain on SAP seems to be dependent on both inhibition 
of the Na+ pump and activation of the renin-angiotensin 
system. The effect of ouabain on DAP, reflecting the pe-
ripheral resistance, seems to be dependent only on the 
renin-angiotensin system. 
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